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The relationship between focal adhesion protein
(FAK) activity and loss of cell-matrix contact during
apoptosis is not entirely clear nor has the role of FAK in
chemically induced apoptosis been studied. We investi-
gated the status of FAK phosphorylation and cleavage in
renal epithelial cells during apoptosis caused by the
nephrotoxicant dichlorovinylcysteine (DCVC). DCVC
treatment caused a loss of cell-matrix contact which was
preceded by a dissociation of FAK from the focal adhe-
sions and tyrosine dephosphorylation of FAK. Paxillin
was also dephosphorylated at tyrosine. DCVC treatment
activated caspase-3 which was associated with cleavage
of FAK. However, FAK cleavage occurred after cells had
already lost focal adhesions indicating that cleavage of
FAK by caspases is not responsible for loss of FAK from
focal adhesions. Accordingly, although inhibition of
caspase activity with zVAD-fmk blocked activation of
caspase-3, FAK cleavage, and apoptosis, it neither af-
fected dephosphorylation nor translocation of FAK or
paxillin. However, zVAD-fmk completely blocked the
cell detachment caused by DCVC treatment. Orthovana-
date prevented DCVC-induced tyrosine dephosphoryl-
ation of both FAK and paxillin; however, it did not in-
hibit DCVC-induced apoptosis and actually potentiated
focal adhesion disorganization and cell detachment.
Thus, FAK dephosphorylation and loss of focal adhe-
sions are not due to caspase activation; however,
caspases are required for FAK proteolysis and cell
detachment.
Apoptosis or programmed cell death is critical for normal
development and tissue homeostasis (1). However, uncon-
trolled apoptosis, as may occur after treatment with cytostatic
chemicals, is a pathophysiological process and is associated
with the occurrence of various human diseases (2, 3). Apoptosis
is characterized by fragmentation of the nucleus, activation of
nucleases, and importantly, activation of the caspase family of
aspartate-directed proteases. The latter cleave a diverse set of
cellular proteins, such as PARP, DNA-dependent protein ki-
nase, protein kinase C-d, gelsolin, b-catenin, GAS-2, fodrin, and
FAK1 (4–15). Presumably, the change of function (gain or loss)
caused by proteolysis of multiple target proteins contributes to
apoptosis. Thus, the proteolysis of cytoskeleton-associated pro-
teins is most likely involved in the morphological alterations
observed during apoptosis in vitro and in vivo, i.e. membrane
blebbing and “rounding up” of cells.
Maintenance of cell-matrix contact is an important cell sur-
vival factor (16–21) and loss of cell matrix and cell-cell contact,
or rounding up, is a hallmark of apoptosis. Enforced loss of
cell-matrix interactions of endothelial and epithelial cells, is
sufficient to initiate a form of apoptosis that has been termed
“anoikis” (18, 19). The fact that apoptotic cells detach from
their substratum raises the possibility that the signaling
events leading to anoikis are either the same as, or may overlap
with signals that lead to other forms of apoptosis, for example,
induced by chemicals or FasL/tumor necrosis factor.
Cell-matrix interactions occur at the closest contact between
the cell and the substratum: the focal adhesions. This is a
complex network of (cytoskeletal) proteins that links the fila-
mentous actin (F-actin) cytoskeletal network through cell ad-
hesion molecules, so called integrins, to the extracellular ma-
trix (16, 17, 22, 23). Integrin engagement by the extracellular
matrix results in activation of focal adhesion kinase (FAK).
FAK is a 125-kDa protein tyrosine kinase that is critical in
transmission of signals from the focal adhesion to the cyto-
plasm after cell attachment (24, 25). After activation, FAK
interacts with a variety of focal adhesion (signaling) macromol-
ecules, including the adaptor proteins paxillin and Grb-2, the
cytoskeletal proteins tensin and talin, and signal transduction
molecules such as Src, Fyn, and phosphoinositide 3-kinase (22,
23, 26–33). These interactions link integrin-mediated adhesion
to downstream signaling cascades. For example, the SH2 do-
main of phosphoinositide 3-kinase binds FAK at the tyrosine
autophosphorylation site (Tyr397) (34). Cell adhesion results in
the activation of phosphoinositide 3-kinase and the down-
stream signaling molecule c-Akt/PKB (35, 36). Adhesion also
leads to activation of the mitogen-activated protein kinase
pathway, p70 ribosomal S6 kinase and protein kinase C (37–
39). Activation of Akt/PKB, mitogen-activated protein kinase,
or protein kinase C serve as anti-apoptotic stimuli (40–45).
Although FAK is one of the few proteins that is phosphorylated
on tyrosine residues upon cell adhesion, its role in the activa-
tion of all of the above signaling pathways is still under inves-
tigation. Nonetheless, it seems clear that FAK is important for
focal adhesion signaling and cell attachment and migration.
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Although the downstream effector molecules responsible for
FAK signaling are not completely known, there is increasing
evidence that FAK is involved in anoikis and, perhaps, other
forms of apoptosis (12–15, 46–50). For example, microinjection
of peptides that compete for FAK-integrin association, and also
antibodies directed against FAK itself can induce apoptosis in
fibroblasts (48). Treatment of tumor cells with FAK antisense
oligonucleotides also leads to apoptosis (47). Moreover, overex-
pression of constitutively active FAK prevents anoikis (46, 51).
Furthermore, during apoptosis FAK is cleaved both in adher-
ent and non-adherent cell lines (12–15), a process that depends
on caspase activation since zVAD-fmk blocks FAK cleavage.
Recombinant FAK is also cleaved by recombinant caspase-3
and -6 into fragments of approximately 44, 77, and 85 kDa
corresponding to the fragments seen during FAK cleavage in
apoptotic cells (13, 15). Despite the fact that FAK cleavage
and/or inactivation provides an attractive explanation for the
loss of cell-matrix interactions that occur during apoptosis,
there is little or no evidence supporting this assumption, nor
has the role of FAK signaling been addressed in chemically
induced models of apoptotic cell death. Furthermore, the ma-
jority of studies have been performed in immortalized or trans-
formed cells; little is known about the involvement of FAK
signaling and cell detachment in vivo or in primary cultures of
normal epithelial cells. Therefore, we have investigated the
role of FAK in chemically induced apoptosis in primary cul-
tures of renal proximal tubular epithelial cells.
The renal proximal tubule epithelial cells (RPTE) are an
important target for a variety of nephrotoxic chemicals as well
as ischemia/reperfusion injury (52, 53). Death of renal epithe-
lial cells is associated with detachment of viable RPTE from the
extracellular matrix, both in vitro and in vivo, an effect that is
related to redistribution of integrins and loss of focal adhesion
organization (54–59). Conditions that prevent attachment of
the renal epithelial cell line Madin-Darby canine kidney also
cause apoptosis, suggesting that there is a relationship be-
tween cell detachment and cell death (19, 46). Therefore, we
investigated the role of FAK phosphorylation and its cleavage
during loss of focal adhesion integrity and apoptosis of primary
cultures of rat RPTE using the well characterized nephrotoxi-
cant S-(1,2-dichlorovinyl)-L-cysteine (DCVC) (57, 58, 60–65).
DCVC is metabolized by a b-lyase to a reactive acylating me-
tabolite that covalently modifies cellular macromolecules (60–
62); DCVC induces apoptosis of RPTE in culture (58, 65). Cell
death of primary cultured RPTE caused by DCVC treatment is
preceded by disorganization of the F-actin cytoskeletal network
and dissolution of focal adhesions (57, 58). Thus, this compound
is a useful agent to study the role of focal adhesion disturbance
and cell detachment in apoptosis of primary cultures of kidney
epithelial cells.
To study the relationship between focal adhesion assembly,
FAK phosphorylation, and apoptosis and to investigate
whether disturbances in FAK signaling may contribute to
chemically induced apoptosis in RPTE, we determined FAK
localization and phosphorylation. These effects were correlated
with activation of caspases and the occurrence of apoptosis
after DCVC treatment. Apoptosis of RPTE was preceded by an
early tyrosine dephosphorylation of both FAK and the FAK-
associated protein paxillin. Dephosphorylation was also asso-
ciated with an early redistribution of FAK and paxillin from the
focal adhesion. The cleavage of FAK was a late event and
followed the activation of caspases. The general caspase inhib-
itor zVAD-fmk blocked the DCVC-induced increase in caspase
activity, FAK cleavage, and apoptosis; however, FAK dephos-
phorylation and translocation still occurred. The data suggest
that FAK dephosphorylation and dissolution of the focal adhe-
sions precede cleavage of FAK by caspases during chemically
induced apoptosis of renal epithelial cells.
EXPERIMENTAL PROCEDURES
Materials—Fetal bovine serum was from Life Technologies (Grand
Island, NY). Dulbecco’s modified Eagle’s medium/Ham’s F-12, bovine
serum albumin fraction V, cholera toxin, insulin, antibiotic were from
Sigma. Epidermal growth factor was from Upstate Biotechnology Inc.
(UBI, Lake Placid, NY). N,N9-Diphenyl-p-phenylenediamine (DPPD)
was from Kodak (Rochester, NY). Benzyloxycarbonyl-Val-Ala-Asp-flu-
oromethylketone (zVAD-fmk) was purchased from Bachem (Bubendorf,
Switzerland). Rhodamine-phalloidin was from Molecular Probes (Eu-
gene, CA). DCVC was synthesized as described (61).
Isolation, Culturing, and Treatment of Rat Renal Proximal Tubular
Epithelial Cells (RPTE)—RPTE were isolated by collagenase perfusion
and separated by density centrifugation using Nycodenz as described
(63, 66). Cells were cultured on rat tail collagen (Collaborative Re-
search, Bedford, MA) coated dishes in Dulbecco’s modified Eagle’s me-
dium/Ham’s F-12 containing 1% (v/v) fetal bovine serum, 0.5 mg/ml
bovine serum albumin, 10 mg/ml insulin, 10 ng/ml epidermal growth
factor, 10 ng/ml cholera toxin, and antibiotics as described (57, 67).
Cells were maintained at 37 °C in a humidified atmosphere of 95% air
and 5% carbon dioxide and fed every other day. Cells were used after
they had reached confluency 6 to 9 days after plating.
Confluent monolayers of RPTE in 24-well dishes containing coated
glass coverslips, 6-well or 10-cm dishes, were washed with Earle’s
balanced salt solution (EBSS) twice. Thereafter cells were treated with
DCVC in EBSS in a final volume of 1, 2, or 10 ml, respectively, for 4 h.
To study events that are related to apoptosis, cells were treated with
DCVC in the presence of DPPD (20 mM; 10 mM stock in dimethyl
sulfoxide) which blocks necrotic cell death but allows the onset of
apoptosis (58, 65). The inhibitors zVAD-fmk (100 mM; 100 mM stock in
dimethyl sulfoxide) or Na3VO4 (5, 10, 25, or 50 mM; 100 mM stock in
water) were added simultaneously with DCVC. Following treatment
with DCVC for 4 h, cells were allowed to recover in complete medium
containing DPPD (20 mM) with or without the above inhibitors.
Cell Death and Caspase Activation Assays—Cell death was measured
by the release of lactate dehydrogenase (LDH) in the culture medium as
described (62). Percentage of cell death was calculated from the amount
of LDH release caused by treatment with toxicants relative to the
amount released by 0.1% (w/v) Triton X-100, i.e. 100% release. To
determine the percentage of cell detachment, floating cells (superna-
tant) and adherent cells (obtained after trypsinization; see below) were
collected separately. Cells were counted using a hemocytometer and the
percentage of cell detachment was calculated as floating cells/total cells
times 100%. DNA laddering was determined by agarose gel electro-
phoresis. Cells were harvested by scraping the adherent cells which
were then combined with floating cells present in the culture medium.
After centrifugation, the cell pellet was washed once with ice-cold PBS
by centrifugation, lysed with lysis buffer (10 mM Tris, 1 mM EDTA, and
0.2% (w/v) Triton X-100, pH 7.4), and incubated on ice for 20 min. Cell
debris was removed by centrifugation; the supernatant was treated
with RNase (60 mg/ml) for 1 h at 37 °C and then with proteinase K (120
mg/ml) for 1 h at 50 °C. The DNA was precipitated with 0.5 M NaCl and
an equal volume of isopropyl alcohol and separated by electrophoresis
on 1% agarose gels. Nuclear fragmentation was determined in cells
cultured on collagen-coated glass coverslips. After fixation with 3.7%
(w/v) formaldehyde, cells were stained with 1 mg/ml Hoechst 33258 in
PBS. After washing with PBS, coverslips were mounted and viewed
using a Nikon epifluorescence microscope. In some experiments nuclear
staining was combined with immunofluorescence staining (see below).
Apoptosis was also determined by cell cycle analysis. Both floating
and adherent cells that were trypsinized were pooled and fixed in 90%
ethanol (220 °C). After washing cells twice with PBS/EDTA (1 mM),
cells were resuspended in PBS-EDTA containing 10 mg/ml RNase A and
7.5 mM propidium iodide. After 30 min incubation at room temperature
the cell cycle was analyzed by flow cytometry (FACScan, Becton Dick-
inson) and the percentage of cells present in sub-G0/G1 was calculated
using the LYSIS software (Becton Dickinson).
Caspase activity was assayed as follows. Briefly, attached and de-
tached cells were harvested and collected by centrifugation as above.
The cell pellet was taken up in lysis buffer (10 mM HEPES, 40 mM
b-glycerophosphate, 50 mM NaCl, 2 mM MgCl2, and 5 mM EGTA) and
subjected to three cycles of freezing and thawing. Equal amounts of cell
proteins were used in a caspase assay using acetyl-DEVD-AMC (25 mM;
Research Biochemicals Int., Natick, MA) as a substrate. Fluorescence
derived from release of the AMC moiety was followed using a fluores-























cence plate reader (HTS 7000 Bioassay reader; Perkin-Elmer, Norwalk,
CT). Caspase activity was calculated as picomole/min/mg cell protein
using AMC as a standard.
Immunoprecipitation and Western Blotting—For immunoprecipita-
tion studies cells were plated in 10-cm Petri dishes coated with collagen.
After treatment with toxicant cells were harvested in a Tris-sucrose-
EGTA (TSE) buffer containing 10 mM Tris/HCl (pH 7.4), 150 mM su-
crose, 1 mM EGTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl
fluoride, 10 mg/ml leupeptin, 10 mg/ml aprotonin, 1 mM Na3VO4, and 50
mM sodium fluoride. After sonication, 500 mg of cell protein was incu-
bated overnight with 1 volume of RIPA buffer (50 mM Tris-HCl (pH 7.4),
150 mM NaCl, 1 mM EDTA, 1.0% (w/v) sodium deoxycholate, 1% (w/v)
Triton X-100, and 0.1% (w/v) sodium dodecyl sulfate), with protease and
phosphatase inhibitors as described for TSE buffer making a total
volume of 1 ml. Thereafter samples were cleared by centrifugation and
the supernatant was incubated with 4 mg of FAK antibody (Transduc-
tion Laboratories, Lexington, KY) for 4 h followed by another 2-h
incubation with protein G-coated Sepharose 4B Fast Flow beads (Sig-
ma). Beads were pelleted by brief centrifugation and washed three
times with low-salt buffer (50 mM HEPES, 150 mM NaCl, 1 mM EDTA,
and 0.1% (w/v) Nonidet P-40 (pH 7.4), including protease and phospha-
tase inhibitors). Proteins were eluted from the beads by boiling samples
for 5 min in 40 ml of SDS-PAGE sample preparation buffer containing
b-mercaptoethenol. Proteins in equal volumes of sample were separated
by SDS-PAGE followed by Western blotting using standard techniques.
In other experiments, cleared samples were used for the immunopre-
cipitation of tyrosine-phosphorylated proteins using agarose-conju-
gated anti-phosphotyrosine (4G10) (Upstate Biotechnology, Lake
Placid, NY). Blots were probed with 1 mg/ml mouse monoclonal anti-
FAK antibody, 0.25 mg/ml mouse monoclonal anti-paxillin (Transduc-
tion Laboratories), or 1 mg/ml 4G10 anti-phosphotyrosine monoclonal
antibody (Upstate Biotechnology). For detection, horseradish peroxi-
dase-conjugated anti-mouse secondary antibody and the ECL method
were used (Amersham).
Immunofluorescence and Imaging Techniques—Immunofluorescence
studies were carried out using cells cultured on collagen-coated glass
coverslips in 24-well dishes. After treatment with toxicants cells were
fixated with 3.7% formaldehyde for 10 min followed by 3 washes with
PBS. After cell lysis and blocking with PBS, 0.2% (w/v) Triton X-100,
0.5% (w/v) BSA (pH 7.4) (PTB) cells were stained for FAK, PAX, or PY
using 10, 5, and 10 mg/ml monoclonal antibody diluted in PTB as
described previously. During the staining period of the cells with sec-
ondary fluorescein isothiocyanate-labeled anti-mouse antibody the F-
actin cytoskeletal network was labeled with rhodamine-phalloidin (Mo-
lecular Probes, Eugene, OR; 0.3 unit/ml). After a final wash of the cells
with PBS the DNA was stained with Hoechst 33258 as above. Cells
were mounted on glass slides using Aqua-Poly/Mount (Polysciences
Inc., Warrington, PA). Cells were viewed using a Bio-Rad 600 MRC
confocal laser scanning microscope. Representative images for the dif-
ferent treatment conditions were printed using a Mitsubishi color video
printer.
Statistical Analysis—Student’s t test was used to determine if there
was a significant difference between two means (p , 0.5). When mul-
tiple means were compared, significance was determined by a one-way
analysis of variance (ANOVA; p , 0.5). For ANOVA analysis, letter
designations are used to indicate significant differences. Means with a
common letter designation are not different; those with a different
letter designation are significantly different from all other means with
different letter designations. For example, a mean designated as A is
significantly different from a mean designated B, but neither is differ-
ent from a mean designated AB.
RESULTS
DCVC Causes Activation of Caspases and Cleavage of FAK in
RPTE—Apoptosis is associated with the activation of caspases.
Treatment of RPTE with DCVC resulted in the cleavage of
pro-caspase-3 (32 kDa) into the active caspase-3 fragment (17
kDa); this was associated with increased caspase-3 activity as
determined using acetyl-DEVD-AMC as a substrate (Fig. 1).
Activation of caspase-3 preceded DNA fragmentation and cell
death as determined by formation of 180–200-base pair nucleo-
somal “ladders” and release of LDH into the medium (Fig. 2). A
general caspase inhibitor, zVAD-fmk, completely blocked the
DCVC-induced cleavage of caspase-3 and activation of DEV-
FIG. 1. Effect of zVAD on caspase activation by DCVC. RPTE
were treated with DCVC in EBSS containing DPPD (20 mM) and after
4 h cells were allowed to recover in complete medium containing 20 mM
DPPD for another 4 h (t 5 8 h). At 2, 4, 6, or 8 h after the addition of
DCVC (0.25 mM) pro-caspase-3 cleavage into the 17 kDa caspase-3
fragment (A) and caspase activity (B) were determined. The concentra-
tion-dependent effect of DCVC on caspase cleavage (C) and caspase
activity (D) as well as the effect of zVAD-fmk (100 mM) on the caspase
activation by DCVC (0.25 mM) was determined 8 h after the start of the
incubation. Caspase-3 cleavage and overall caspase activity were deter-
mined as described under “Experimental Procedures.” Caspase-3 cleav-
age shown is representative for four independent experiments. Caspase
activity data shown are mean 6 S.E. of four independent experiments
(n 5 4).
FIG. 2. Effect of zVAD on DCVC-induced cytotoxicity. RPTE
were treated with DCVC (0.25 mM) in EBSS containing 20 mM DPPD in
the presence or absence of zVAD-fmk (100 mM) for 4 h followed by
recovery. Cell cycle analysis (A, left panel: without zVAD-fmk; right
panel, with zVAD-fmk) and DNA fragmentation (B) were determined
12 h after the start of the incubation as described under “Experimental
Procedures.” The data shown are representative for four independent
experiments. Cell death (C) was determined by analyzing the relative
release of LDH from cells in the culture medium compared with total
LDH present and was expressed as % cell death. Data shown are
mean 6 S.E. of four independent experiments (n 5 4).























Dase activity (Fig. 1), DNA fragmentation, and the increase in
apoptotic cells seen as a sub-G1/G0 population by flow cytom-
etry (Fig. 2). Although zVAD-fmk clearly blocked all the events
that are characteristic for apoptosis, it did not block the overall
cell killing as determined by the release of LDH from the cells
(Fig. 2).
Since DCVC-induced apoptosis of RPTE is associated with
impaired cell adhesion (57, 58, 65), and because FAK is cleaved
by caspases in cell-free systems as well as in intact cells in vitro
(12–15), we determined whether DCVC-induced caspase acti-
vation is associated with FAK cleavage in RPTE. A major
increase in the cleavage of FAK into two fragments with ap-
proximate sizes of 70 and 77 kDa was observed 6 h after DCVC
treatment, but not before (Fig. 3). Cleavage of FAK correlated
with activation of caspase-3 by DCVC (Fig. 1).
DCVC-induced Translocalization of FAK Precedes Caspase
Activation—We next investigated the fate of FAK during
apoptosis at the cellular and biochemical level. First we deter-
mined whether cleavage of FAK was associated with altered
localization of FAK by (immuno)staining of RPTE treated with
DCVC for FAK and F-actin. Although FAK cleavage and
caspase activation is first observed 6 h after DCVC treatment,
FAK redistribution from the focal adhesions to the cytoplasm
was observed after 2 h and was maximal 4 h after DCVC
treatment (Fig. 4). Loss of FAK from focal adhesions was ac-
companied by an increased FAK staining in the cytosolic com-
partment and to some extent in the nucleus. Altered FAK
localization was temporally associated with disruption and col-
lapse of the F-actin cytoskeletal network, but FAK did not
co-localize with F-actin (Fig. 4). Thus, altered FAK localization
clearly preceded cleavage of FAK by caspases, suggesting that
an altered focal adhesion ultrastructure is most likely not
caused by caspase activation.
DCVC-induced Translocation of FAK Is Associated with Loss
of Tyrosine Phosphorylation—The results indicated that
DCVC-induced loss of FAK from focal adhesions was independ-
FIG. 3. DCVC causes cleavage of FAK. RPTE were treated with
DCVC as described in the legend to Fig. 1 and FAK cleavage was
determined by Western blotting as described under “Experimental Pro-
cedures.” A, to determine the time dependent effect of DCVC (0.25 mM)
on FAK cleavage samples were taken at 2, 4, 6, and 8 h after start of the
experiment. B, at 8 h after start of the experiment the concentration
dependent effect of DCVC on FAK cleavage was determined. Data
shown are representative for four independent experiments (n 5 4).
FIG. 4. DCVC causes a redistribution of FAK. RPTE were treated with DCVC (0.25 or 1 mM) as described in the legend to Fig. 1. After 4 h
cells were fixated and double-stained for FAK and F-actin. Stained cells were viewed using a Bio-Rad confocal laser scanning microscope. Data are
representative for three independent experiments (n 5 3). Note that FAK translocates to the cytosol and the nuclear compartment and does not
co-localize with the collapsed F-actin network.























ent of caspase activation; therefore, other signals must be in-
volved. Integrin engagement by extracellular matrix results in
autophosphorylation of FAK and subsequent formation of focal
adhesions (22–25). Since DCVC disrupts focal adhesions in
RPTE (57, 58), we determined whether DCVC-induced loss of
FAK from focal adhesions was associated with loss of tyrosine
phosphorylation of FAK. Indeed, DCVC caused a dose-depend-
ent dephosphorylation of FAK at tyrosine as demonstrated by
immunoprecipitation of FAK followed by Western blotting with
anti-phosphotyrosine and anti-FAK antibody. FAK was almost
FIG. 5. DCVC causes tyrosine dephosphorylation of FAK. RPTE
were treated with increasing concentration of DCVC (0.1, 0.25, 0.5, and
1.0 mM) in EBSS in the presence of DPPD (20 mM). After 4 h cells were
harvested and equal amounts of cell protein were immunoprecipitated
with anti-FAK and immunoprecipitated proteins were separated by
SDS-PAGE followed by Western blotting. Blots were probed for anti-
phosphotyrosine (PY) and anti-FAK (A). Intensity of the bands were
scanned by densitometry to determine the ratio of PY/pp125 FAK. The
ratio was expressed as fold over control (B). Data are representative for
three independent experiments (n 5 3).
FIG. 6. DCVC causes a loss of paxillin phosphorylation. RPTE
were treated with increasing concentration of DCVC (0.1, 0.25, 0.5, and
1.0 mM) in EBSS in the presence of DPPD (20 mM). After 4 h cells were
harvested and total cell protein was separated by SDS-PAGE followed
by Western blotting for anti-phosphotyrosine (A). Equal amounts of cell
protein were immunoprecipitated with agarose-conjugated anti-PY fol-
lowed by SDS-PAGE and Western blotting. Blots were probed with
monoclonal anti-paxillin (aPAX) (B). Results shown are representative
of three independent experiments (n 5 3).
FIG. 7. DCVC causes a translocation of paxillin from the focal adhesion to the F-actin stress fibers. RPTE were treated with DCVC
(0.25 or 1 mM) in EBSS in the presence of DPPD (20 mM). After 4 h cells were fixed for 5 min with 3.7% formaldehyde. Cells were stained for paxillin
and F-actin as described under “Experimental Procedures.” Stained cells were viewed using a Bio-Rad confocal laser scanning microscope. Note
the exact co-localization of paxillin with the collapsed F-actin network.























completely dephosphorylated after a 4-h treatment with 0.25
mM DCVC (Fig. 5), a time point at which cleavage of FAK had
not yet occurred (Fig. 3). The increased intensity of FAK bands
in the DCVC-treated cells (see Fig. 5) may be explained by a
translocation of FAK from the cytoskeleton fraction to the
cytosol, thus resulting in a higher recovery of FAK from these
samples for immunoprecipitation.
DCVC-induced Loss of FAK Phosphorylation Is Associated
with Loss of Paxillin Phosphorylation—The data suggested
that focal adhesion disturbances and FAK dephosphorylation
occur upstream of caspase activation. Many focal adhesion-
associated proteins are also phosphorylated at tyrosine resi-
dues, and some are direct substrates for FAK. To investigate
whether disturbances in tyrosine phosphorylation contributed
to DCVC-induced impaired cell adhesion and cell death, we
first evaluated the alterations in total cell protein-phosphoty-
rosine content. DCVC caused a dose dependent decrease in
protein-phosphotyrosine from proteins of ;60–70 kDa and pro-
teins with a molecular mass around 120–130 kDa (Fig. 6A).
Paxillin is a 68-kDa cytoskeletal adaptor protein that co-local-
izes with focal adhesions in a variety of cell types and is heavily
phosphorylated on tyrosine residues. Immunoprecipitation of
phosphotyrosine-containing proteins with anti-phosphoty-
rosine antibody followed by electrophoresis and Western blot-
ting for paxillin demonstrated that the broad protein band of
;60–70 kDa contained the cytoskeletal adaptor protein paxil-
lin (Fig. 6B). Thus DCVC treatment causes a loss of protein
phosphotyrosine from paxillin as well.
Next, we determined the effect of dephosphorylation on the
cellular localization of paxillin. DCVC caused a rapid loss of
paxillin from focal adhesions and an increase in paxillin stain-
ing in the cytosol (Fig. 7). Intense staining of paxillin was also
observed in dots that co-localized with the collapsed F-actin
cytoskeleton, suggesting that even though paxillin was lost
from the focal adhesion, it remained associated with F-actin
(Fig. 7). To further evaluate this translocation of paxillin to the
F-actin network, cells were permeabilized just prior to fixation
to determine cytoskeletal association. Within 2 h after DCVC
treatment, co-localization of cytoskeleton-associated paxillin
with the F-actin network was observed; after 4 h paxillin com-
pletely co-localized with large F-actin aggregates present in the
cytosol (not shown). Paxillin did not co-localize with the cortical
F-actin cytoskeletal network. A similar association with the
F-actin network was observed with talin, another focal adhe-
sion-associated cytoskeletal protein (data not shown). Although
both paxillin and FAK co-localized in focal adhesions in control
cells, FAK and paxillin no longer co-localized after DCVC treat-
ment (compare Fig. 4 with Fig. 7).
Inhibition of Protein Tyrosine Phosphatases Increases FAK
and Paxillin Tyrosine Phosphorylation without Affecting
Caspase Activation and Apoptosis—The results indicated that
nephrotoxicants cause dephosphorylation of both paxillin and
FAK prior to loss of cell-matrix contact and cell death. To
investigate the role of phosphatases in dephosphorylation of
FAK and paxillin, cells were incubated with an inhibitor of
protein tyrosine phosphatases, orthovanadate. As expected,
treatment of RPTE with orthovanadate alone caused an overall
increase of protein tyrosine phosphorylation. In addition, im-
munoprecipitation experiments indicated that both FAK and
paxillin had approximately 4-fold more phosphotyrosine after
orthovanadate compared with control cells (Fig. 8). Although
DCVC alone caused a complete loss of phosphotyrosine on
paxillin and FAK, FAK tyrosine phosphorylation after expo-
sure to DCVC/orthovanadate remained approximately the
same as orthovanadate-treated control cells. Thus, orthovana-
date can block DCVC-induced dephosphorylation of both pax-
illin and FAK suggesting that an imbalance in protein tyrosine
kinase and phosphatase activity is responsible.
To determine if preventing DCVC-induced dephosphoryl-
ation of paxillin and FAK was associated with loss of focal
adhesion integrity or cell adhesion, we determined the effect of
orthovanadate on DCVC-induced translocation of FAK and
paxillin as well as cell attachment. Although orthovanadate
itself had only a minor effect on FAK localization, it actually
potentiated the DCVC-induced redistribution of FAK (Fig. 9).
Similar results were obtained for the redistribution of paxillin
(data not shown). Because DCVC-induced translocation of FAK
is associated with impaired cell adhesion, we checked whether
the potentiation of DCVC-induced FAK translocation by or-
thovanadate was associated with enhancement of RPTE
detachment. Indeed, orthovanadate potentiated the cell de-
tachment caused by DCVC (Table I). Thus, not only the
phosphorylation itself but rather the cellular localization of
FAK, in combination with tyrosine phosphorylation, seems
important in the regulation of cell adhesion.
Although maintaining the phosphorylation of both FAK and
paxillin with orthovanadate did not protect against cell detach-
ment, the possibility existed that orthovanadate protected
against cell death. To investigate this we determined the
DCVC-induced caspase activation, a measure of the activation
of the apoptotic machinery, as well as cell death. Orthovana-
date did not inhibit the DCVC-induced activation of caspases
(Fig. 10). Moreover, DCVC-induced release of LDH and forma-
tion of a population of cells with sub-G0/G1 DNA content, i.e.
apoptotic cells, was unaffected (Fig. 10). Finally, although or-
thovanadate increased tyrosine phosphorylation of FAK (see
above), this did not have an effect on the amount of FAK that
was cleaved by caspases (Fig. 10).
Caspases Mediate Cleavage of FAK and Cell Detachment
Caused by DCVC—Having characterized the temporal rela-
FIG. 8. Orthovanadate prevents DCVC-induced tyrosine de-
phosphorylation of paxillin and FAK. RPTE were treated with
DCVC (0.25 mM) in EBSS containing 20 mM DPPD in the presence or
absence of Na3VO4 (25 mM). After 4 h cells were harvested. Total cell
protein was separated by SDS-PAGE followed by Western blotting;
blots were probed with anti-phosphotyrosine (PY). Note the increase of
total PY-protein after treatment with Na3VO4 (A). Equal amounts of
protein were either immunoprecipitated with anti-PY or anti-pp125
FAK. Immunoprecipitated PY-proteins were separated by SDS-PAGE
followed by Western blotting; blots were probed with anti-paxillin
(aPAX) (B). Immunoprecipitated pp125 FAK was also separated by
SDS-PAGE followed by Western blotting; blots were probed with an-
ti-PY (aPY) and after stripping the blots were re-probed with anti-
pp125 FAK (aFAK) (C). Intensity of the pp125 FAK after staining for
either anti-PY or anti-pp125 FAK, were scanned by densitometry, and
the ratio PY/FAK was calculated and expressed as fold over control (D).























FIG. 9. Orthovanadate does not prevent translocation of FAK from the focal adhesions to the cytosol. RPTE treated with DCVC (0.25
mM) in EBSS containing containing 20 mM DPPD in the presence or absence of Na3VO4 (25 mM). After 4 h cells were fixed and double-stained for
pp125 FAK and F-actin. Stained cells were viewed using a Bio-Rad confocal laser scanning microscope. Data are representative for three
independent experiments (n 5 3).























tionship between FAK and paxillin localization and dephospho-
rylation after DCVC treatment, we determined whether
DCVC-induced activation of caspases is involved in the dephos-
phorylation of FAK and paxillin by determining the phospho-
tyrosine content of both proteins after DCVC treatment in the
presence or absence of zVAD-fmk. As might be predicted from
the disparity in the time dependence for FAK cleavage versus
dephosphorylation, zVAD-fmk did not inhibit the DCVC-in-
duced tyrosine dephosphorylation of cellular proteins (Fig. 11)
including FAK and paxillin.
Next we determined whether the cleavage of FAK was de-
pendent on caspase activity. Therefore cells were treated with
DCVC in the presence of z-VAD-fmk. Inhibition of DCVC-
induced caspase activation by z-VAD-fmk (see Fig. 1) was as-
sociated with a complete inhibition of FAK cleavage (Fig. 11).
This indicates that the FAK cleavage is due to caspase
activation.
A clear increase of floating RPTE was only observed after 8 h
treatment with DCVC. This was also a time point when
caspase activity and FAK cleavage was clearly increased.
Therefore, the possibility existed that cell detachment was
dependent on caspase activity. Inhibition of caspases with
zVAD-fmk, which blocked the cleavage of FAK, did not have an
effect on the DCVC-induced rounding up of cells. However,
z-VAD-fmk clearly inhibited the cell detachment caused by
DCVC (Fig. 11). To determine whether this was related to a
protection against a disturbance of the focal adhesions, we
analyzed the focal adhesion organization after DCVC treat-
ment in the presence of z-VAD-fmk. Z-VAD-fmk did not block
any of the DCVC-induced alterations of the focal adhesions and
F-actin network after 4 h treatment (not shown). Thus,
caspase-mediated proteolysis of cellular (cytoskeletal) proteins,
including FAK, does not mediate loss of the focal adhesion and
F-actin network organization during apoptosis.
DISCUSSION
These studies on the temporal relationship between FAK
dephosphorylation, translocation, and cleavage and the activa-
tion of the apoptotic machinery during apoptosis of primary
cultured renal proximal tubular epithelial cells allow us to
draw two important conclusions. First, FAK dephosphorylation
caused by DCVC precedes activation of the apoptotic machin-
ery, i.e. caspases, and is independent of caspase cleavage. De-
phosphorylation also precedes the proteolysis of FAK. Although
FIG. 10. Orthovanadate does not inhibit DCVC-induced cytotoxicity. RPTE were treated with DCVC (0.25 mM) as described in the legend
to Fig. 1 in the absence or presence of Na3VO4 (25 mM). After 8 h caspase-3 and FAK cleavage (A) and caspase activity (B) were determined as
described in the legends to Figs. 1 and 3. After 12 h the % cell death as determined by the relative LDH release, and the % of cells present in the
sub-G0/G1 as measured by flow cytometry analysis, was determined (C) as described under “Experimental Procedures.” The DCVC-induced DNA
fragmentation was also analyzed after 12 h (D). Data shown are representative for four independent experiments (A an D) or mean 6 S.E.
(n 5 4; C and D).
TABLE I
Effect of orthovanadate on DCVC-induced cell detachment of RPTE
RPTE were treated with DCVC (0.25 mM) as described in the legend
to Fig. 1 in the absence or presence of Na3VO4 (25 mM). After 12 h the
% detached cells was determined as described under “Experimental
Procedures.” Data shown are the mean 6 S.E. of four independent
experiments (n 5 4).
Treatment % Detached cells
Control 2.5 6 0.9A
DCVC 47.3 6 1.6B
Na3VO4 0.8 6 0.4
A
DCVC/Na3VO4 62.1 6 4.0
C























we have only described the effects of DCVC, similar observa-
tions were made with another nephrotoxicant, cis-platin, indi-
cating that our observations are also important in other forms
of nephrotoxicant induced cytotoxicity (59).2 FAK cleavage has
been reported before in other models of apoptosis (12–15), but
the temporal relationship between FAK dephosphorylation,
FAK translocation, and FAK cleavage has not been studied.
Thus, to our knowledge, this is the first report that indicates
that FAK dephosphorylation precedes activation of caspases
and cleavage of FAK during apoptosis. Second, in this model,
dephosphorylation of FAK is closely associated with loss of
cell-matrix interactions, but even when FAK dephosphoryl-
ation is complete, cells remain attached to the substratum.
Although caspase activity is not involved in the impairment of
focal adhesion signaling, it appears that cleavage of FAK and
other cytoskeletal proteins is required for irreversible detach-
ment of cells from the substratum. Possibly, cleavage of FAK
and other cytoskeletal proteins not only causes cell detachment
but also prevents the reattachment and spreading of injured
cells. This may have considerable consequences in renal injury,
since blocking cell reattachment prevents the attendant tubu-
lar obstruction that occurs after renal injury (54, 55). Thus, our
studies provide new insights into the role of focal adhesion
signaling in renal injury.
Although disruption of focal adhesion signaling through FAK
clearly precedes cell detachment after chemically induced apo-
ptosis, the data also suggest that caspase activation is not
responsible for the former. Rather, the data indicate that tox-
icant-induced dephosphorylation of focal adhesion proteins in-
cluding FAK may contribute to loss of focal adhesions and
cell-matrix interactions. Forced loss of cell-matrix interactions
of RPTE, by keeping trypsinized RPTE in suspension, also
results in caspase activation and apoptosis.3 Therefore, the
present observations fit a model in which loss of focal adhesion
architecture and signaling is a trigger for chemically induced
activation of caspases culminating in apoptosis; FAK may have
a central role. Indeed, FAK and related family members play
an important role in other models of apoptosis. Blocking the
interaction of FAK with b-integrin during cell adhesion induces
apoptosis (48). Expression of a constitutively active FAK, a
CD2-FAK chimer that localizes to focal adhesions, but not
chimers containing FAK kinase-dead mutants, inhibit anoikis
(46, 51). In contrast to the anti-apoptotic role of FAK, overex-
pression of proline-rich tyrosine kinase 2, also known as cellu-
lar adhesion kinase b, a FAK related non-receptor protein
tyrosine kinase that also localizes at focal adhesion, induces
apoptosis (50). Thus, different FAK family members may have
opposing roles in regulating apoptosis. FAK activation seems a
cellular survival factor and FAK dephosphorylation may lead to
decreased activity of signaling cascades that otherwise would block
the apoptotic machinery. For example, cell adhesion results in
activation of Akt/PKB, which is involved in phosphorylation of the
pro-apoptotic Bcl-2 family member Bad (35, 36, 40–42). This phos-
phorylation results in inactivation of the anti-apoptotic function of
Bad and, as a consequence, protection against apoptosis (40–42).
The relationship between chemically induced dephosphorylation
and translocation of FAK and perturbation of downstream signal
transduction cascades in the control of apoptosis warrants further
investigations.
Cell detachment during apoptosis is likely to occur in two
steps: loss of cell-to-cell contact and then loss of cell-substra-
tum adhesion, i.e. the reverse of the steps in organizing an
epithelial layer. Both steps seem important in controlling
apoptosis (19, 46, 68). Our results indicate that FAK dephos-
phorylation and translocation as well as caspase-mediated
FAK cleavage were associated with renal cell detachment dur-
ing apoptosis. Yet, only caspase-mediated cleavage of FAK
seems related to the final renal cell detachment: zVAD-fmk
blocked cell detachment completely without affecting either the
dephosphorylation and translocation of FAK or the disruption
of focal adhesions. Thus, our data suggest that FAK dephos-
phorylation and loss of focal adhesions are closely associated
with loss of cell-matrix contact, but not irreversible detachment
which actually requires caspase activation since zVAD blocked
detachment but not focal adhesion disruption. Thus, cells may
still adhere to the substratum even though they have com-
pletely disrupted focal adhesions. This may be related to the
fact that cell adhesion not only depends on cell-matrix but also
on cell-cell interactions. Besides FAK, other cytoskeletal pro-
teins that are involved in cell-cell interactions, e.g. b-catenin
and fodrin (non-erythroid spectrin), have been identified as
substrates for caspases (8, 11). Moreover, Gas2 and gelsolin,
whose functions are directly related to the organization of the
F-actin cytoskeletal network, are also caspase substrates (7, 9).
Thus, the caspase-mediated cleavage of several cytoskeletal
proteins, including FAK, may be required for the complete loss
of cell-matrix as well as cell-cell interactions during apoptosis.
Cleavage of these proteins may actually ensure that the cell
does not reattach and proliferate at a distant site. Moreover,
FAK cleavage will prevent (re)activation of anti-apoptotic sig-
naling cascades, for example, through Akt/PKB, derived from
focal adhesions thereby preventing survival of cells that are
otherwise destined to die. Indeed, overexpression of the C-
terminal fragment of FAK prevents autophosphorylation of
endogenous FAK upon cell adhesion (15), and FAK cleavage is
associated with loss of interaction between FAK and paxillin
(14). Thus, these data indicate that FAK cleavage is linked to
inhibition of focal adhesion-related signaling events as well as
loss of protein-protein interactions.
The implications of cell reattachment in metastasis of tumor
cells are well known. However, also during renal injury, it is
clear that reattachment of dying or injured cells, through inte-
2 B. Van de Water and J. L. Stevens, unpublished observations.
3 B. Van de Water, unpublished observations.
FIG. 11. zVAD-fmk blocks DCVC-induced FAK cleavage and
cell detachment without affecting tyrosine dephosphorylation.
RPTE were treated with DCVC (0.25 mM) as described in the legend to
Fig. 1 in the absence or presence of zVAD-fmk (100 mM). After 4 h total
cell lysates were separated by SDS-PAGE followed by Western blotting
and blots were probed with anti-phosphotyrosine (PY) (A). FAK cleav-
age was determined after 8 h as described in the legend to Fig. 3 (B).
Shown are representative immunoblots of four independent experi-
ments. Cell detachment was quantified after 12 h as described under
“Experimental Procedures” and expressed as mean of % detached
cells 6 S.E. (n 5 4).























grin-mediated signaling, has important pathophysiological im-
plications since it contributes to the tubular obstruction that
exacerbates renal injury (54, 55). In this scenario, pharmaco-
logical intervention of caspase activity could be used to block
cell detachment after a renal insult and, thereby, alleviate
tubular obstruction. It would be expected that such a treatment
would reduce the severity of the renal injury. Thus, our studies
provide new insights into possible modulation of acute renal
injury.
Although it is clear that FAK dephosphorylation by itself is
not sufficient to cause cell detachment, the exact role of
caspase-mediated cleavage of FAK in this process needs fur-
ther investigation. We studied the involvement of FAK in
chemically induced apoptosis, however, also deregulation of
other focal adhesion-associated signaling molecules that are
implicated in focal adhesion regulation and/or control of cell
death, e.g. c-Src, Fyn, and Crk, may be involved. Regardless of
the role of other focal adhesion proteins, FAK cleavage during
apoptosis will be important to prevent focal adhesion reassem-
bly of cells that are otherwise supposed to die by apoptosis.
In summary, the present findings demonstrate that FAK
dephosphorylation precedes toxicant-induced activation of
caspases and subsequent cleavage of FAK. The fact that focal
adhesion-mediated signal transduction is fundamental for cell
survival of normal epithelial cells and that many focal adhe-
sion-associated molecules have oncogenic potential, most likely
by preventing anoikis (46), warrants future investigation on
the role of other focal adhesion-associated signaling molecules
in the control of (chemically induced) apoptosis.
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